Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DARATUMUMAB vs DARIFENACIN HYDROBROMIDE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DARATUMUMAB vs DARIFENACIN HYDROBROMIDE: Safety Overview

Metric DARATUMUMAB DARIFENACIN HYDROBROMIDE
Total FAERS Reports 27,387 193
Deaths Reported 3,941 65
Death Rate 14.4% 33.7%
Hospitalizations 10,205 43
Average Patient Age 66.8 yrs 74.5 yrs
% Female Patients 44.5% 80.5%
FDA Approval Date N/A Dec 22, 2004
Manufacturer Janssen Biotech, Inc. Cipla USA Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Discontinued